US20220020463A1 - Method and system to optimize pharmacotherapy - Google Patents
Method and system to optimize pharmacotherapy Download PDFInfo
- Publication number
- US20220020463A1 US20220020463A1 US17/363,242 US202117363242A US2022020463A1 US 20220020463 A1 US20220020463 A1 US 20220020463A1 US 202117363242 A US202117363242 A US 202117363242A US 2022020463 A1 US2022020463 A1 US 2022020463A1
- Authority
- US
- United States
- Prior art keywords
- therapy
- efficacy
- patient
- risk
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000001050 pharmacotherapy Methods 0.000 title claims abstract description 25
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 188
- 238000012544 monitoring process Methods 0.000 claims abstract description 37
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 56
- 238000011156 evaluation Methods 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 19
- 230000003416 augmentation Effects 0.000 claims description 17
- 230000036626 alertness Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000003860 sleep quality Effects 0.000 claims description 9
- 238000011461 current therapy Methods 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 238000003058 natural language processing Methods 0.000 claims description 3
- 230000007958 sleep Effects 0.000 description 20
- 230000006399 behavior Effects 0.000 description 13
- 238000011338 personalized therapy Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 6
- 229960001879 ropinirole Drugs 0.000 description 6
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 5
- 206010041349 Somnolence Diseases 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 229960003089 pramipexole Drugs 0.000 description 5
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 5
- 208000032140 Sleepiness Diseases 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000004622 sleep time Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 229940041701 gabapentin 600 mg Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008667 sleep stage Effects 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02405—Determining heart rate variability
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/053—Measuring electrical impedance or conductance of a portion of the body
- A61B5/0531—Measuring skin impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Detecting, measuring or recording devices for evaluating the respiratory organs
- A61B5/0806—Detecting, measuring or recording devices for evaluating the respiratory organs by whole-body plethysmography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4815—Sleep quality
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4806—Sleep evaluation
- A61B5/4818—Sleep apnoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/486—Bio-feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
- A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
- A61M16/026—Control means therefor including calculation means, e.g. using a processor specially adapted for predicting, e.g. for determining an information representative of a flow limitation during a ventilation cycle by using a root square technique or a regression analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N5/00—Computing arrangements using knowledge-based models
- G06N5/02—Knowledge representation; Symbolic representation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/30—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
- A61B2560/0247—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value
- A61B2560/0257—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value using atmospheric pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1118—Determining activity level
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
Definitions
- the disclosed concept generally relates to therapy and, more particularly, to optimizing pharmacotherapy.
- RLS Restless Legs Syndrome
- RLS can be treated with iron supplementation, dopamine agonists, alpha-2-delta calcium channel ligands, as well as non-pharmacologic interventions, like ensuring good sleep hygiene, avoiding caffeine, and getting regular low-intensity exercise. Also, avoiding exacerbating factors, like sleep deprivation or antidepressants.
- a method of optimizing pharmacotherapy comprises: monitoring one or more characteristics of a patient associated with a condition of the patient and evaluating a baseline severity of the condition of the patient; recommending a selected therapy to the patient based on a therapy efficacy-risk map; evaluating an actual severity of the condition of the patient; evaluating an efficacy of the selected therapy; evaluating a risk score of the selected therapy; and updating the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- a system for optimizing pharmacotherapy comprises: one or more sensing modules structured to monitor one or more characteristics of a patient associated with a condition of the patient; a baseline severity module structured to determine a severity of the condition of the patient; a recommendation module structured to recommend a selected therapy to the patient based on a therapy efficacy-risk map; an actual severity evaluation module structured to evaluate an actual severity of the condition of the patient; a therapy efficacy evaluation module structured to evaluate an efficacy of the selected therapy; a risk evaluation module structured to evaluate a risk score of the selected therapy; and a therapy efficacy-risk map update module structured to update the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- a non-transitory computer readable medium storing one or more programs, including instructions, which when executed by a computer, causes the computer to perform a method of optimizing pharmacotherapy.
- the method comprises: monitoring one or more characteristics of a patient associated with a condition of the patient and evaluating a baseline severity of the condition of the patient; recommending a selected therapy to the patient based on a therapy efficacy-risk map; evaluating an actual severity of the condition of the patient; evaluating an efficacy of the selected therapy; evaluating a risk score of the selected therapy; and updating the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- FIG. 1 is a flowchart of a method of optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept
- FIG. 2 is schematic diagram of a system for optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept
- FIG. 3 is a schematic diagram of a system in a build phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- FIG. 4 is a schematic diagram of a system in a deployment phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- a personalized therapy efficacy-risk map is generated to recommend therapies corresponding to the severity of the patient's condition. Risks and efficacies of the therapies are included in the therapy efficacy-risk map.
- the personalized therapy efficacy-risk map characteristics of a patient are continuously monitored and the risk and efficacy of treatments are evaluated. As the patient is continuously monitored and therapies are tried, the personalized efficacy-risk map is updated to reflect efficacies and risks of the therapies, as well as changes in efficacies and risks of the therapies. In this manner, pharmacotherapy efficacy and risk reduction can be optimized.
- FIG. 1 is a flowchart of a method of optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- the method begins at 100 where a number of behaviors and/or biometrics of a patient are monitored.
- the monitored behaviors and/or biometrics may include RLS objective metrics such as, without limitation, leg movement frequency, intensity, and duration.
- the monitored behaviors and/or biometrics may include sleep metrics such as, without limitation, sleep efficiency, wake after sleep onset, sleep onset latency, total sleep time, a number of awakenings, and sleep stages.
- the monitored behaviors and/or biometrics may include alertness metrics such as, without limitation, nap frequency, nap duration, movement, movement intensity, and behaviors.
- the monitored behaviors and/or biometrics may include behaviors such as, without limitation, sleep hygiene, caffeine intake frequency and timing, and medication intake.
- the monitored behaviors and/or biometrics may be monitored with one or more sensors such as, without limitation, under mattress and/or wearable sensors.
- the monitored behaviors and/or biometrics may also be monitored by patient provided subjective responses.
- the patient response may be gathered through any suitable means such as, without limitation, a digital survey, a chat bot, or any other suitable means for gathering subjective responses.
- a severity of the patient's RLS may be determined.
- the severity may be defined by pre-determined levels (i.e., mild, moderate, severe, and very severe) based on the International RLS Rating Scale.
- Objective RLS related physiological measures such as movement intensity, duration, and frequency may be used to determine the patient's RLS severity level.
- a therapy is recommended to the patient.
- a therapy efficacy-risk map is generated.
- the therapy efficacy-risk map corresponds a therapies to the severity of the patient's condition. Additionally, the therapy efficacy-risk map provides an efficacy and a risk of the therapy.
- An example therapy efficacy-risk map is provided below in Table 1 and an example of a more detailed therapy efficacy-risk map is provided below in Table 2.
- each severity level includes a number of corresponding therapies (e.g., very severe has corresponding therapy IDs 7 and 9).
- each therapy ID corresponds to a particular drug, dose, and dose time.
- therapy ID 7 corresponds to a 0.25 mg/d dose of Pramipexole at 8:00 PM
- therapy ID 9 corresponds to a 0.5 mg/d dose of Pramipexole at 7:00 PM.
- Each therapy also has a corresponding efficacy and risk score.
- the efficacy of score represents the efficacy of the therapy and the risk score represents risks such as side effects and augmentation. Evaluation of the efficacy and risk of therapies will be described in more detail.
- the therapy efficacy-risk map may use population data such as clinical study results, review articles, or questionnaires to generate the efficacy and risk scores of therapies.
- population data such as clinical study results, review articles, or questionnaires
- the therapy efficacy-risk map is updated to be personalized to the patient.
- the efficacy and risk scores of therapies may be evaluated and updated based on patient monitoring.
- the therapy recommended to the patient will be selected from the therapies corresponding to the severity of the patient's condition.
- the selected therapy will maximize efficacy while minimizing the risk score.
- the corresponding solution x will be the best therapy in the list (i.e., the therapy with maximum efficacy and minimum risk). While using a composite cost function is one example of selecting the recommended therapy to maximize efficiency and minimize risk, it will be appreciated that other suitable methods may also be used to select the recommended therapy.
- a risk score threshold may be employed in determining a recommended therapy. For example, the patient's current therapy may be recommended if the risk score is below the risk score threshold. If the risk score of the patient's current therapy is above the risk score threshold, a new therapy may be recommended to the patient. The new therapy may be recommended using the composite cost function described above or any other suitable method.
- the actual severity of the patient's condition during therapy is evaluated.
- the actual severity of the patient's condition is evaluated based on monitored biometrics during a specified monitoring period.
- objective RLS physiological measures such as, without limitation, movement intensity, duration, and frequency may be monitored using one or more sensors.
- the physiological measures may be monitored while the recommended therapy is applied to the patient. For example, the physiological measures may be monitored at night when the therapy is applied to the patient. From the monitored physiological measures, the actual severity of the patient's condition may be evaluated.
- the efficacy of the therapy is evaluated.
- the efficacy of the therapy may be based on a number of factors such as, without limitation, a reduction score of severity, a sleep quality score, and an alertness score.
- the reduction score may include a comparison of the baseline severity (e.g., determined before therapy) and the actual severity (e.g., determined while a therapy is in use).
- the reduction score may be based on a ratio of the actual to baseline severity or a difference between the baseline and actual severity.
- the reduction score may be within a range of 0 to 100, with a score of 100 being the most effective.
- the sleep quality score may be based on a number of sleep metrics such as, without limitation, sleep efficiency, wake after sleep onset, number of awakenings, sleep onset latency, deep sleep percentage, and total sleep time.
- the sleep metrics may be monitored while the therapy is in use.
- the sleep quality score may be within a range of 0 to 100, with a score of 100 being the most effective.
- the alertness score may be based on a number of metrics such as, without limitation, number of naps, duration of naps, movements, movement intensity, and behaviors.
- the metrics for the alertness score may be monitored during the day.
- the alertness score may be within a range of 0 to 100, with a score of 100 being the most effective.
- a severity reduction score, sleep quality score, and alertness score are provided as examples of factors that can be used to evaluate the efficacy of a therapy, it will be appreciated that different factors may be employed. The various factors may be weighted differently to determine the therapy efficacy. For example, in an embodiment, the reduction score and sleep quality score are weighted higher than the alertness score. However, it will be appreciated that different weightings may be used without departing from the disclosed concept.
- the risk score of the therapy is evaluated.
- factors associated with the risk score may be monitored.
- Factors associated with the risk score may include therapy side effects (e.g., dizziness, somnolence, nausea, etc.), therapy augmentation metrics (e.g., movement intensity, duration and frequency), and relevant stressors (e.g., health condition changes and medication changes).
- therapy side effects e.g., dizziness, somnolence, nausea, etc.
- therapy augmentation metrics e.g., movement intensity, duration and frequency
- relevant stressors e.g., health condition changes and medication changes.
- the side effects may be monitored via subjective patient inputs such as text inputs provided to a chat bot, web chat bubble, or other suitable input mechanism, and processed using natural language processing or other suitable processing mechanisms.
- initial risk scores population data such as clinical guidelines or clinical studies may be used to determine the risk score. As the patient is continuously monitored and uses therapies, the initial risk scores may be replaced with personalized risk scores based on the monitoring and risk evaluation of the patient.
- the therapy efficacy-risk map is updated.
- the efficacy and/or risk scores evaluated based on monitoring of the patient replace their corresponding existing efficacy and/or risk scores in the therapy efficacy-risk map.
- the initial therapy efficacy-risk map based on population data is transformed into a personalized efficacy-risk map.
- the personalized therapy efficacy-risk map captures efficacy and risks of therapies personal to the patient, such as when a therapy is more or less effective or present more or less risk to the patient than what the population data suggests.
- the therapy efficacy-risk map such as when augmentation begins to appear after using a therapy for a time or when a therapy loses some efficacy after a period of use. In this manner, the therapy recommended to the patient can continually be optimized.
- the method may have a build phase where therapies are recommended by a therapy provider.
- the efficacies and risks of the therapies may be evaluated through monitoring of the patient and the therapy efficacy-risk map for the patient evolves from a default therapy-severity map to a personalized therapy-severity map.
- the method may move to a deployment phase where the personalized therapy efficacy-risk map is used to recommend a therapy.
- the method may be implement by one or more computing devices, memories, and sensors. For example, monitoring the behaviors and/or biometrics of the patient may be implemented with sensors such as under mattress and/or wearable sensors as well as any suitable computing device for inputting subjective patient responses.
- the method may be implemented on a localized or distributed system. For example, one or more parts of the method may be implemented on a user device, such as a mobile phone, tablet, or computer, as well, parts of the method may be implemented on a remote device such as a server.
- the personalized therapy efficacy-risk map may be stored on the user device or on a server.
- FIG. 2 is schematic diagram of a system 200 for optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- the system 200 includes an alertness sensing module 202 , a sleep metrics sensing module 204 , a baseline RLS severity module 206 , an RLS metrics monitoring module 208 , a selected therapy module 210 , a therapy efficacy evaluation module 212 , an actual RLS severity evaluation module 214 , a build personalized therapy efficacy-risk map module 216 , and an RLS therapy risk evaluation module 218 .
- the alertness sensing module 202 may sense metrics associated with alertness such as nap frequency, nap duration, movement, movement intensity, and behaviors.
- the alertness sensing module 202 may include or receive outputs from one or more sensors such as under mattress and/or wearable sensors.
- the sleep metrics sensing module 204 may sense metrics associated with sleep quality such as sleep efficiency, wake after sleep onset, sleep onset latency, total sleep time, number of awakenings, and sleep stages.
- the sleep metrics sensing module may include or receive outputs from one or more sensors such as under mattress and/or wearable sensors.
- the RLS metrics monitoring module 208 may sense objective metrics associated with RLS such as leg movement frequency, intensity, and duration.
- the RLS metrics monitoring module 208 may include or receive output from one or more sensors such as under mattress and/or wearable sensors.
- the baseline RLS severity module 206 is structured to estimate a baseline severity of the patient's RLS.
- the baseline severity may be defined by pre-determined levels (i.e., mild, moderate, severe, and very severe) based on the International RLS Rating Scale.
- Objective RLS related physiological measures such as movement intensity, duration, and frequency may be used to determine the patient's RLS severity level.
- the baseline RLS severity module 206 may include or be connected to one or more sensors structured to monitor the objective RLS related physiological measures.
- the selected therapy module 210 may identify the selected therapy for the patient. For example, the selected therapy module 210 may receive information on the selected therapy.
- the actual RLS severity module 214 is structured to estimate the actual severity of the patient's RLS. The actual severity may be estimated based on the objective RLS metrics monitored by the RLS metrics monitoring module 208 .
- the therapy efficacy evaluation module 212 is structured to evaluate the efficacy of the therapy. The efficacy may be evaluated as described above with respect to FIG. 1 .
- the RLS therapy risk evaluation module 218 is structured to evaluate the risk of the selected therapy. The risk may be evaluated as described above with respect to FIG. 1 .
- the build personalized therapy efficacy-risk map module 216 is structured to build a personalized therapy risk-efficacy map for the patient based on the actual severity, the selected therapy, the evaluated efficacy of the therapy, and the evaluated risk of the therapy.
- the therapy efficacy-risk map corresponds therapies with levels of severity and includes an evaluation of the efficacy of the therapy and an evaluation of the risk of the therapy.
- the initial therapy efficacy-risk map may be a default map generated by population data. Over time, the therapy efficacy-risk map may be updated based on monitoring and evaluation of the patient to become a personalized therapy efficacy-risk map.
- the system 200 may be implemented as one or more computing devices and sensors.
- the system 200 may be a localized or distributed system.
- the selected therapy module 210 may also store recommendations for therapy.
- the recommendation may be based on maximizing efficacy and minimizing risk, as is described above with respect to FIG. 1 .
- FIG. 3 is a schematic diagram of a system 300 in a build phase for the personal risk history of pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- the system 300 includes an RLS side effects monitoring module 302 , an RLS augmentation metrics monitoring module 304 , a stressor sensing module 306 , a population risk history module 308 , an RLS therapy risk evaluation module 310 , and a build personal risk history module 312 .
- the RLS side effects monitoring module 302 is structured to monitor side effects associated with the selected therapy.
- the RLS side effects monitoring module 302 may include or be connected to one or more devices structured to obtain subjective inputs from the patient associated with side effects.
- the devices may include one more computing devices with a user interface to prompt a user to provide subjective inputs such as free text inputs (e.g., via a chat bot or web chat bubble) related to side effects.
- the devices may also include a natural language processing module to process the inputs.
- the devices may be structured to prompt a user to answer a question associated with side effects and to process the answer to determine whether a side effect is present.
- the RLS augmentation metrics monitoring module 304 is structured to monitor metrics associated with augmentation associated with the selected therapy.
- the augmentation metrics may include, without limitation, movement intensity, duration and frequency.
- the RLS augmentation metrics monitoring module may include or be connected to one or more sensors structured to monitor the augmentation metrics.
- the stressor sensing module 306 is structured to monitor stressors associated with the selected therapy.
- the stressors may include, without limitation, health condition changes and medication changes.
- the stressor sensing module 306 may include or be connected to one or more sensors structured to monitor the stressors.
- the stressor sensing module 306 may also include or be connected to one or more devices structured to receive inputs associated with the stressors.
- the population risk history module 308 is structured to gather and/or provide a risk history of a selected therapy from population data such as clinical studies or guidelines. As has been described herein, an initial risk score associated with a therapy may be generated from population data.
- the population risk history module 308 may include or be connected to a storage device including risks associated with therapies.
- the RLS therapy risk evaluation module 310 is structured to determine a risk score of a therapy based on one or more of the side effects, augmentation metrics, stressors, and risk history.
- the build personal risk history module 312 is structured to build and store a personal risk history based on risk scores determined by the RLS therapy risk evaluation module 310 .
- the build personal risk history module 312 may include or be connected to a storage device that stores therapies and their associated risk scores. Initially, the build personal risk history module 312 may use an initial risk history based on population data. As the patient is monitored and evaluated, the build personal risk history module 312 may update the initial risk history by replacing initial risk scores with risk scores determined by the RLS therapy risk evaluation module.
- the system 300 may be implemented as one or more computing devices and sensors.
- the system 300 may be a localized or distributed system.
- the system 300 may be used in a build phase when little monitoring of the patient has been performed and population risk history has to be used to evaluate therapy risk. Over time, the system 300 may transition to or be replaced by a system in a deployment phase where the personal risk history is more developed based on monitoring and evaluation of the patient.
- An example of a system in the deployment phase will be described in more detail with respect to FIG. 4 .
- the system 300 may include one or more interfaces.
- the interfaces may be, for example and without limitations, user interfaces available in device applications to a patient and/or care provider.
- the interfaces may provide for input from multiple sources.
- the sources may include direct input from the user (e.g., questionnaires, free text input, etc.), direct input from a care provider, data such as articles and studies, and input from sensors.
- Sensors may include sensors on a user device (e.g., temperature, time, position, weather, or other sensors), wearable sensors (e.g., watch, ring, patch, etc.), or other sensors positioned within a home or other area (e.g., temperature, mattress, blanket, pillow, etc.).
- the sensors may be used to gather real-time data associated with the patient and their environment.
- the information from multiple sources may be used to continuously monitor the patient for symptoms and exacerbations associated with their condition and/or their current therapy.
- the system 300 may also include one or more storage and processing device to store and evaluate the collected data.
- FIG. 4 is a schematic diagram of a system 400 in a deployment phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept.
- the system includes an RLS side effects monitoring module 402 , an RLS augmentation metrics monitoring module 404 , and a stressor sensing module 406 which operate similar to their corresponding components in FIG. 3 .
- the system 400 also includes a personal risk history module 408 and an RLS therapy risk evaluation module 410 .
- the personal risk history module 408 is structured to store a personal risk history associated with the patient.
- the personal risk history may be the same or similar to one built using the system 300 of FIG. 3 , and includes risk scores determined based on monitoring and evaluation of the patient.
- the RLS therapy risk evaluation module 410 is structured to determine a risk score associated with a selected therapy based on one or more of the side effects, augmentation metrics, stressors, and the personal risk history.
- the RLS therapy risk evaluation module 410 is also structured to update the personal risk history with each new determined risk score. In this manner, the personal risk history is continually update as the patient is monitored and evaluated while utilizing therapies.
- the risk scores determined by the system 400 may be employed in the systems or methods of FIG. 1 or 2 to build and/or update the therapy efficacy-risk map.
- the risk score determined based on monitoring and evaluation of the patient may be used to replace an existing risk score in the therapy efficacy-risk map.
- an embodiment of the disclosed concept may be embodied on a non-transitory computer readable medium storing one or more programs, including instructions, which when executed by a computer, causes the computer to perform the method described with respect to FIG. 1 .
- any reference signs placed between parentheses shall not be construed as limiting the claim.
- the word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim.
- several of these means may be embodied by one and the same item of hardware.
- the word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements.
- any device claim enumerating several means several of these means may be embodied by one and the same item of hardware.
- the mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Artificial Intelligence (AREA)
- Theoretical Computer Science (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Databases & Information Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Mathematical Physics (AREA)
- Evolutionary Computation (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Computing Systems (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 63/054,197, filed on 20 Jul. 2020. This application is hereby incorporated by reference herein.
- The disclosed concept generally relates to therapy and, more particularly, to optimizing pharmacotherapy.
- Restless Legs Syndrome (RLS) has been estimated to impact between 3.9 to 14.3% of the adult population. Diagnosis of RLS requires the patient to express an urge to move the legs, typically associated with accompanying unpleasant sensations that begin to worsen as the patient remains still for an extended period of time. Typically the urge to move the legs is worse during the evening and night than during the day (most often at sleep onset) and is temporarily relieved by movement. RLS symptoms typically need to occur at least 2x/week and have significant side effects (e.g. daytime sleepiness, mood issues, etc.) in order to be considered for clinical treatment. The prevalence of RLS is significantly higher in women than in men and is a common disorder during pregnancy, especially toward the third trimester.
- RLS can be treated with iron supplementation, dopamine agonists, alpha-2-delta calcium channel ligands, as well as non-pharmacologic interventions, like ensuring good sleep hygiene, avoiding caffeine, and getting regular low-intensity exercise. Also, avoiding exacerbating factors, like sleep deprivation or antidepressants.
- Patients with milder symptoms that occur intermittently may be treated with non-pharmacologic therapy. For more severe symptoms, or when non-pharmacologic therapy is not successful, pharmacotherapy (i.e., drug therapy) is often used. Although there is continuing research on the best methods of treatment of RLS, the efficacy of pharmacotherapy tends to decrease over time and/or lead to augmentation. Lowered efficacy and augmentation may result in a physician altering drug dosing and/or dose timing, or changing the drug completely. Some subjectivity or trial and error may be involved in altering pharmacotherapy regimes for an RLS patient.
- There remains room for improvement in pharmacotherapy for RLS or other conditions.
- Accordingly, it is an object of the disclosed concept to provide a system and method to optimize pharmacotherapy treatment of conditions such as RLS or other conditions.
- As one aspect of the disclosed concept, a method of optimizing pharmacotherapy comprises: monitoring one or more characteristics of a patient associated with a condition of the patient and evaluating a baseline severity of the condition of the patient; recommending a selected therapy to the patient based on a therapy efficacy-risk map; evaluating an actual severity of the condition of the patient; evaluating an efficacy of the selected therapy; evaluating a risk score of the selected therapy; and updating the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- As one aspect of the disclosed concept, a system for optimizing pharmacotherapy comprises: one or more sensing modules structured to monitor one or more characteristics of a patient associated with a condition of the patient; a baseline severity module structured to determine a severity of the condition of the patient; a recommendation module structured to recommend a selected therapy to the patient based on a therapy efficacy-risk map; an actual severity evaluation module structured to evaluate an actual severity of the condition of the patient; a therapy efficacy evaluation module structured to evaluate an efficacy of the selected therapy; a risk evaluation module structured to evaluate a risk score of the selected therapy; and a therapy efficacy-risk map update module structured to update the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- As one aspect of the disclosed concept, a non-transitory computer readable medium storing one or more programs, including instructions, which when executed by a computer, causes the computer to perform a method of optimizing pharmacotherapy. The method comprises: monitoring one or more characteristics of a patient associated with a condition of the patient and evaluating a baseline severity of the condition of the patient; recommending a selected therapy to the patient based on a therapy efficacy-risk map; evaluating an actual severity of the condition of the patient; evaluating an efficacy of the selected therapy; evaluating a risk score of the selected therapy; and updating the therapy efficacy-risk map based on the evaluated efficacy and risk score of the selected therapy.
- These and other objects, features, and characteristics of the disclosed concept, as well as the methods of operation and functions of the related elements of structure and the combination of parts and economies of manufacture, will become more apparent upon consideration of the following description and the appended claims with reference to the accompanying drawings, all of which form a part of this specification, wherein like reference numerals designate corresponding parts in the various figures. It is to be expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the invention.
-
FIG. 1 is a flowchart of a method of optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept; -
FIG. 2 is schematic diagram of a system for optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept; -
FIG. 3 is a schematic diagram of a system in a build phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept; and -
FIG. 4 is a schematic diagram of a system in a deployment phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept. - As required, detailed embodiments of the disclosed concept are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the disclosed concept in virtually any appropriately detailed structure.
- As used herein, the singular form of “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.
- Directional phrases used herein, such as, for example and without limitation, top, bottom, left, right, upper, lower, front, back, and derivatives thereof, relate to the orientation of the elements shown in the drawings and are not limiting upon the claims unless expressly recited therein.
- In accordance with an embodiment of the disclosed concept, optimized pharmacotherapy recommendations are provided. For example, a personalized therapy efficacy-risk map is generated to recommend therapies corresponding to the severity of the patient's condition. Risks and efficacies of the therapies are included in the therapy efficacy-risk map. In building the personalized therapy efficacy-risk map, characteristics of a patient are continuously monitored and the risk and efficacy of treatments are evaluated. As the patient is continuously monitored and therapies are tried, the personalized efficacy-risk map is updated to reflect efficacies and risks of the therapies, as well as changes in efficacies and risks of the therapies. In this manner, pharmacotherapy efficacy and risk reduction can be optimized.
-
FIG. 1 is a flowchart of a method of optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept. The method begins at 100 where a number of behaviors and/or biometrics of a patient are monitored. The monitored behaviors and/or biometrics may include RLS objective metrics such as, without limitation, leg movement frequency, intensity, and duration. The monitored behaviors and/or biometrics may include sleep metrics such as, without limitation, sleep efficiency, wake after sleep onset, sleep onset latency, total sleep time, a number of awakenings, and sleep stages. The monitored behaviors and/or biometrics may include alertness metrics such as, without limitation, nap frequency, nap duration, movement, movement intensity, and behaviors. The monitored behaviors and/or biometrics may include behaviors such as, without limitation, sleep hygiene, caffeine intake frequency and timing, and medication intake. The monitored behaviors and/or biometrics may be monitored with one or more sensors such as, without limitation, under mattress and/or wearable sensors. The monitored behaviors and/or biometrics may also be monitored by patient provided subjective responses. The patient response may be gathered through any suitable means such as, without limitation, a digital survey, a chat bot, or any other suitable means for gathering subjective responses. - As part of the monitoring behaviors and biometrics, a severity of the patient's RLS may be determined. In an embodiment, the severity may be defined by pre-determined levels (i.e., mild, moderate, severe, and very severe) based on the International RLS Rating Scale. Objective RLS related physiological measures such as movement intensity, duration, and frequency may be used to determine the patient's RLS severity level.
- At 102 a therapy is recommended to the patient. As part of recommending a therapy, a therapy efficacy-risk map is generated. The therapy efficacy-risk map corresponds a therapies to the severity of the patient's condition. Additionally, the therapy efficacy-risk map provides an efficacy and a risk of the therapy. An example therapy efficacy-risk map is provided below in Table 1 and an example of a more detailed therapy efficacy-risk map is provided below in Table 2.
-
TABLE 1 RLS Severity Therapy Past Efficacy Past Risk Score Level ID (F1) (F2) very severe 7 78 10 very severe 9 65 5 moderate 4 80 15 moderate 11 70 15 moderate 2 50 5 severe 1 68 15 severe 8 75 25 severe 6 60 20 mild 3 90 20 mild 5 84 16 mild 10 77 20 -
TABLE 2 RLS Past Severity Therapy Past Risk Dose Dose Level ID Efficacy Score Drug mg/d Time Side Effects Augmentation very 7 78 10 Pramipexole 0.25 8:00 PM none mild severe very 9 65 5 Pramipexole 0.5 7:00 PM somnolence mild severe moderate 4 80 15 Ropinirole 0.5 8:00 PM none none moderate 11 70 15 Gabapentin 600 mg 8:00 PM somnolence, mild enacarbil dizziness moderate 2 50 5 Ropinirole 0.25 8:00 PM nausea moderate severe 1 68 15 Ropinirole 0.25 8:00 PM nausea mild severe 8 75 25 Pramipexole 0.25 7:00 PM somnolence moderate severe 6 60 20 Ropinirole 0.5 7:00 PM nausea moderate mild 3 90 20 Ropinirole 0.25 8:00 PM none none mild 5 84 16 Ropinirole 0.5 7:00 PM nausea none mild 10 77 20 Gabapentin 600 mg 8:00 PM none mild enacarbil - As shown in the example therapy efficacy-risk map, each severity level includes a number of corresponding therapies (e.g., very severe has corresponding therapy IDs 7 and 9). In an example embodiment, each therapy ID corresponds to a particular drug, dose, and dose time. For example, therapy ID 7 corresponds to a 0.25 mg/d dose of Pramipexole at 8:00 PM and therapy ID 9 corresponds to a 0.5 mg/d dose of Pramipexole at 7:00 PM. Each therapy also has a corresponding efficacy and risk score. The efficacy of score represents the efficacy of the therapy and the risk score represents risks such as side effects and augmentation. Evaluation of the efficacy and risk of therapies will be described in more detail. When initially generated, the therapy efficacy-risk map may use population data such as clinical study results, review articles, or questionnaires to generate the efficacy and risk scores of therapies. However, as will be described in more detail herein, through continuous monitoring of the patient through various therapies, the therapy efficacy-risk map is updated to be personalized to the patient. For example, the efficacy and risk scores of therapies may be evaluated and updated based on patient monitoring.
- In an embodiment, the therapy recommended to the patient will be selected from the therapies corresponding to the severity of the patient's condition. The selected therapy will maximize efficacy while minimizing the risk score. In an embodiment, to maximize efficacy while minimizing the risk score, a composite cost function may be used such as F(x)=W1*F1(x)−W2F2(x) where x is a vector in the solution space (i.e., it includes medication, dosing, dosing timing and duration), F1(x) is the corresponding efficacy of the therapy, F2(x) is the corresponding risk score of the therapy, W1 is a weighting of the efficacy, and W2 is a weighting of the risk score. By finding the maximum of the composite cost function, the corresponding solution x will be the best therapy in the list (i.e., the therapy with maximum efficacy and minimum risk). While using a composite cost function is one example of selecting the recommended therapy to maximize efficiency and minimize risk, it will be appreciated that other suitable methods may also be used to select the recommended therapy.
- In some example embodiments, a risk score threshold may be employed in determining a recommended therapy. For example, the patient's current therapy may be recommended if the risk score is below the risk score threshold. If the risk score of the patient's current therapy is above the risk score threshold, a new therapy may be recommended to the patient. The new therapy may be recommended using the composite cost function described above or any other suitable method.
- At 104 the actual severity of the patient's condition during therapy is evaluated. In an embodiment, the actual severity of the patient's condition is evaluated based on monitored biometrics during a specified monitoring period. For example, objective RLS physiological measures such as, without limitation, movement intensity, duration, and frequency may be monitored using one or more sensors. The physiological measures may be monitored while the recommended therapy is applied to the patient. For example, the physiological measures may be monitored at night when the therapy is applied to the patient. From the monitored physiological measures, the actual severity of the patient's condition may be evaluated.
- At 106, the efficacy of the therapy is evaluated. The efficacy of the therapy may be based on a number of factors such as, without limitation, a reduction score of severity, a sleep quality score, and an alertness score. The reduction score may include a comparison of the baseline severity (e.g., determined before therapy) and the actual severity (e.g., determined while a therapy is in use). The reduction score may be based on a ratio of the actual to baseline severity or a difference between the baseline and actual severity. In an example embodiment, the reduction score may be within a range of 0 to 100, with a score of 100 being the most effective.
- The sleep quality score may be based on a number of sleep metrics such as, without limitation, sleep efficiency, wake after sleep onset, number of awakenings, sleep onset latency, deep sleep percentage, and total sleep time. The sleep metrics may be monitored while the therapy is in use. In an example embodiment, the sleep quality score may be within a range of 0 to 100, with a score of 100 being the most effective.
- The alertness score may be based on a number of metrics such as, without limitation, number of naps, duration of naps, movements, movement intensity, and behaviors. The metrics for the alertness score may be monitored during the day. In an example embodiment, the alertness score may be within a range of 0 to 100, with a score of 100 being the most effective.
- While a severity reduction score, sleep quality score, and alertness score are provided as examples of factors that can be used to evaluate the efficacy of a therapy, it will be appreciated that different factors may be employed. The various factors may be weighted differently to determine the therapy efficacy. For example, in an embodiment, the reduction score and sleep quality score are weighted higher than the alertness score. However, it will be appreciated that different weightings may be used without departing from the disclosed concept.
- At 108, the risk score of the therapy is evaluated. As part of monitoring the patient, factors associated with the risk score may be monitored. Factors associated with the risk score may include therapy side effects (e.g., dizziness, somnolence, nausea, etc.), therapy augmentation metrics (e.g., movement intensity, duration and frequency), and relevant stressors (e.g., health condition changes and medication changes). In an embodiment, the side effects may be monitored via subjective patient inputs such as text inputs provided to a chat bot, web chat bubble, or other suitable input mechanism, and processed using natural language processing or other suitable processing mechanisms.
- For initial risk scores, population data such as clinical guidelines or clinical studies may be used to determine the risk score. As the patient is continuously monitored and uses therapies, the initial risk scores may be replaced with personalized risk scores based on the monitoring and risk evaluation of the patient.
- At 110, the therapy efficacy-risk map is updated. In an embodiment, the efficacy and/or risk scores evaluated based on monitoring of the patient replace their corresponding existing efficacy and/or risk scores in the therapy efficacy-risk map. In this manner, over time as the patient is monitored and uses therapies, the initial therapy efficacy-risk map based on population data is transformed into a personalized efficacy-risk map. The personalized therapy efficacy-risk map captures efficacy and risks of therapies personal to the patient, such as when a therapy is more or less effective or present more or less risk to the patient than what the population data suggests. Additionally, through continuous monitoring and evaluation, changes in efficacy and risk of therapies over time are captured in the therapy efficacy-risk map, such as when augmentation begins to appear after using a therapy for a time or when a therapy loses some efficacy after a period of use. In this manner, the therapy recommended to the patient can continually be optimized.
- In some embodiments, one or more steps of the method may be omitted or modified. For example, the method may have a build phase where therapies are recommended by a therapy provider. As the patient uses therapies, the efficacies and risks of the therapies may be evaluated through monitoring of the patient and the therapy efficacy-risk map for the patient evolves from a default therapy-severity map to a personalized therapy-severity map. Over time, as the patient has tried different therapies, the method may move to a deployment phase where the personalized therapy efficacy-risk map is used to recommend a therapy.
- The method may be implement by one or more computing devices, memories, and sensors. For example, monitoring the behaviors and/or biometrics of the patient may be implemented with sensors such as under mattress and/or wearable sensors as well as any suitable computing device for inputting subjective patient responses. The method may be implemented on a localized or distributed system. For example, one or more parts of the method may be implemented on a user device, such as a mobile phone, tablet, or computer, as well, parts of the method may be implemented on a remote device such as a server. For example, the personalized therapy efficacy-risk map may be stored on the user device or on a server. Some examples of systems for implementing parts of the method will be described in more detail herein.
-
FIG. 2 is schematic diagram of asystem 200 for optimizing pharmacotherapy in accordance with an example embodiment of the disclosed concept. Thesystem 200 includes analertness sensing module 202, a sleepmetrics sensing module 204, a baselineRLS severity module 206, an RLSmetrics monitoring module 208, a selectedtherapy module 210, a therapyefficacy evaluation module 212, an actual RLSseverity evaluation module 214, a build personalized therapy efficacy-risk map module 216, and an RLS therapyrisk evaluation module 218. - The
alertness sensing module 202 may sense metrics associated with alertness such as nap frequency, nap duration, movement, movement intensity, and behaviors. Thealertness sensing module 202 may include or receive outputs from one or more sensors such as under mattress and/or wearable sensors. The sleepmetrics sensing module 204 may sense metrics associated with sleep quality such as sleep efficiency, wake after sleep onset, sleep onset latency, total sleep time, number of awakenings, and sleep stages. The sleep metrics sensing module may include or receive outputs from one or more sensors such as under mattress and/or wearable sensors. The RLSmetrics monitoring module 208 may sense objective metrics associated with RLS such as leg movement frequency, intensity, and duration. The RLSmetrics monitoring module 208 may include or receive output from one or more sensors such as under mattress and/or wearable sensors. Together, thealertness sensing module 202, sleepmetrics sensing module 204, and RLSmetrics monitoring module 208 may be used to monitor biometrics of a patient. - The baseline
RLS severity module 206 is structured to estimate a baseline severity of the patient's RLS. In an embodiment, the baseline severity may be defined by pre-determined levels (i.e., mild, moderate, severe, and very severe) based on the International RLS Rating Scale. Objective RLS related physiological measures such as movement intensity, duration, and frequency may be used to determine the patient's RLS severity level. The baselineRLS severity module 206 may include or be connected to one or more sensors structured to monitor the objective RLS related physiological measures. - The selected
therapy module 210 may identify the selected therapy for the patient. For example, the selectedtherapy module 210 may receive information on the selected therapy. The actualRLS severity module 214 is structured to estimate the actual severity of the patient's RLS. The actual severity may be estimated based on the objective RLS metrics monitored by the RLSmetrics monitoring module 208. - The therapy
efficacy evaluation module 212 is structured to evaluate the efficacy of the therapy. The efficacy may be evaluated as described above with respect toFIG. 1 . The RLS therapyrisk evaluation module 218 is structured to evaluate the risk of the selected therapy. The risk may be evaluated as described above with respect toFIG. 1 . - The build personalized therapy efficacy-
risk map module 216 is structured to build a personalized therapy risk-efficacy map for the patient based on the actual severity, the selected therapy, the evaluated efficacy of the therapy, and the evaluated risk of the therapy. As described above, the therapy efficacy-risk map corresponds therapies with levels of severity and includes an evaluation of the efficacy of the therapy and an evaluation of the risk of the therapy. The initial therapy efficacy-risk map may be a default map generated by population data. Over time, the therapy efficacy-risk map may be updated based on monitoring and evaluation of the patient to become a personalized therapy efficacy-risk map. - The
system 200 may be implemented as one or more computing devices and sensors. Thesystem 200 may be a localized or distributed system. - In some embodiments, the selected
therapy module 210 may also store recommendations for therapy. The recommendation may be based on maximizing efficacy and minimizing risk, as is described above with respect toFIG. 1 . -
FIG. 3 is a schematic diagram of asystem 300 in a build phase for the personal risk history of pharmacotherapy in accordance with an example embodiment of the disclosed concept. Thesystem 300 includes an RLS sideeffects monitoring module 302, an RLS augmentationmetrics monitoring module 304, astressor sensing module 306, a populationrisk history module 308, an RLS therapyrisk evaluation module 310, and a build personalrisk history module 312. - The RLS side
effects monitoring module 302 is structured to monitor side effects associated with the selected therapy. The RLS sideeffects monitoring module 302 may include or be connected to one or more devices structured to obtain subjective inputs from the patient associated with side effects. For example and without limitation, the devices may include one more computing devices with a user interface to prompt a user to provide subjective inputs such as free text inputs (e.g., via a chat bot or web chat bubble) related to side effects. The devices may also include a natural language processing module to process the inputs. For example, the devices may be structured to prompt a user to answer a question associated with side effects and to process the answer to determine whether a side effect is present. - The RLS augmentation
metrics monitoring module 304 is structured to monitor metrics associated with augmentation associated with the selected therapy. The augmentation metrics may include, without limitation, movement intensity, duration and frequency. The RLS augmentation metrics monitoring module may include or be connected to one or more sensors structured to monitor the augmentation metrics. - The
stressor sensing module 306 is structured to monitor stressors associated with the selected therapy. The stressors may include, without limitation, health condition changes and medication changes. Thestressor sensing module 306 may include or be connected to one or more sensors structured to monitor the stressors. Thestressor sensing module 306 may also include or be connected to one or more devices structured to receive inputs associated with the stressors. - The population
risk history module 308 is structured to gather and/or provide a risk history of a selected therapy from population data such as clinical studies or guidelines. As has been described herein, an initial risk score associated with a therapy may be generated from population data. The populationrisk history module 308 may include or be connected to a storage device including risks associated with therapies. - The RLS therapy
risk evaluation module 310 is structured to determine a risk score of a therapy based on one or more of the side effects, augmentation metrics, stressors, and risk history. The build personalrisk history module 312 is structured to build and store a personal risk history based on risk scores determined by the RLS therapyrisk evaluation module 310. For example, the build personalrisk history module 312 may include or be connected to a storage device that stores therapies and their associated risk scores. Initially, the build personalrisk history module 312 may use an initial risk history based on population data. As the patient is monitored and evaluated, the build personalrisk history module 312 may update the initial risk history by replacing initial risk scores with risk scores determined by the RLS therapy risk evaluation module. - The
system 300 may be implemented as one or more computing devices and sensors. Thesystem 300 may be a localized or distributed system. In an embodiment, thesystem 300 may be used in a build phase when little monitoring of the patient has been performed and population risk history has to be used to evaluate therapy risk. Over time, thesystem 300 may transition to or be replaced by a system in a deployment phase where the personal risk history is more developed based on monitoring and evaluation of the patient. An example of a system in the deployment phase will be described in more detail with respect toFIG. 4 . - In some embodiments of the disclosed concept, the
system 300 may include one or more interfaces. The interfaces may be, for example and without limitations, user interfaces available in device applications to a patient and/or care provider. In some embodiments, the interfaces may provide for input from multiple sources. The sources may include direct input from the user (e.g., questionnaires, free text input, etc.), direct input from a care provider, data such as articles and studies, and input from sensors. Sensors may include sensors on a user device (e.g., temperature, time, position, weather, or other sensors), wearable sensors (e.g., watch, ring, patch, etc.), or other sensors positioned within a home or other area (e.g., temperature, mattress, blanket, pillow, etc.). The sensors may be used to gather real-time data associated with the patient and their environment. The information from multiple sources may be used to continuously monitor the patient for symptoms and exacerbations associated with their condition and/or their current therapy. Thesystem 300 may also include one or more storage and processing device to store and evaluate the collected data. -
FIG. 4 is a schematic diagram of asystem 400 in a deployment phase for evaluating risk of pharmacotherapy in accordance with an example embodiment of the disclosed concept. The system includes an RLS sideeffects monitoring module 402, an RLS augmentationmetrics monitoring module 404, and astressor sensing module 406 which operate similar to their corresponding components inFIG. 3 . Thesystem 400 also includes a personalrisk history module 408 and an RLS therapyrisk evaluation module 410. - The personal
risk history module 408 is structured to store a personal risk history associated with the patient. The personal risk history may be the same or similar to one built using thesystem 300 ofFIG. 3 , and includes risk scores determined based on monitoring and evaluation of the patient. The RLS therapyrisk evaluation module 410 is structured to determine a risk score associated with a selected therapy based on one or more of the side effects, augmentation metrics, stressors, and the personal risk history. The RLS therapyrisk evaluation module 410 is also structured to update the personal risk history with each new determined risk score. In this manner, the personal risk history is continually update as the patient is monitored and evaluated while utilizing therapies. - The risk scores determined by the
system 400 may be employed in the systems or methods ofFIG. 1 or 2 to build and/or update the therapy efficacy-risk map. For example, the risk score determined based on monitoring and evaluation of the patient may be used to replace an existing risk score in the therapy efficacy-risk map. - While some embodiments have been described above related to optimizing treatment of RLS, it will be appreciated that the disclosed concept is also applicable to treatment of other conditions. Additionally, while some embodiments have been described in association with pharmacotherapy, it will be appreciated that the disclosed concept may also be applied to different types of therapies.
- It will also be appreciated that an embodiment of the disclosed concept may be embodied on a non-transitory computer readable medium storing one or more programs, including instructions, which when executed by a computer, causes the computer to perform the method described with respect to
FIG. 1 . - Although the invention has been described in detail for the purpose of illustration based on what is currently considered to be the most practical and preferred embodiments, it is to be understood that such detail is solely for that purpose and that the invention is not limited to the disclosed embodiments, but, on the contrary, is intended to cover modifications and equivalent arrangements that are within the spirit and scope of the appended claims. For example, it is to be understood that the present invention contemplates that, to the extent possible, one or more features of any embodiment can be combined with one or more features of any other embodiment.
- In the claims, any reference signs placed between parentheses shall not be construed as limiting the claim. The word “comprising” or “including” does not exclude the presence of elements or steps other than those listed in a claim. In a device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The word “a” or “an” preceding an element does not exclude the presence of a plurality of such elements. In any device claim enumerating several means, several of these means may be embodied by one and the same item of hardware. The mere fact that certain elements are recited in mutually different dependent claims does not indicate that these elements cannot be used in combination.
Claims (15)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/363,242 US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
EP21751771.3A EP4182950A1 (en) | 2020-07-20 | 2021-07-16 | Method and system to optimize pharmacotherapy for restless legs syndrome (rls) |
PCT/EP2021/070048 WO2022017989A1 (en) | 2020-07-20 | 2021-07-16 | Method and system to optimize pharmacotherapy for restless legs syndrome (rls) |
CN202180059498.7A CN116210057A (en) | 2020-07-20 | 2021-07-16 | Method and system for optimizing medication |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063054197P | 2020-07-20 | 2020-07-20 | |
US17/363,242 US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220020463A1 true US20220020463A1 (en) | 2022-01-20 |
Family
ID=77265057
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/132,424 Pending US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
US17/363,242 Pending US20220020463A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize pharmacotherapy |
US17/363,714 Pending US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/106,827 Active 2042-02-03 US11837106B2 (en) | 2020-07-20 | 2020-11-30 | System and method to monitor and titrate treatment for high altitude-induced central sleep apnea (CSA) |
US17/132,503 Pending US20220020492A1 (en) | 2020-07-20 | 2020-12-23 | Predicting orthosomnia in an individual |
US17/132,424 Pending US20220020286A1 (en) | 2020-07-20 | 2020-12-23 | Optimized effectiveness based sleep aid management |
US17/138,272 Pending US20220016371A1 (en) | 2020-07-20 | 2020-12-30 | System and method for osa prevention and pap therapy weaning |
US17/138,242 Pending US20220016369A1 (en) | 2020-07-20 | 2020-12-30 | System and method for determining and providing personalized pap therapy recommendations for a patient |
US17/363,353 Pending US20220020468A1 (en) | 2020-07-20 | 2021-06-30 | Method and system to optimize therapy efficacy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/363,714 Pending US20220020461A1 (en) | 2020-07-20 | 2021-06-30 | Contextualized personalized insomnia therapy regimen, system, and method |
Country Status (5)
Country | Link |
---|---|
US (8) | US11837106B2 (en) |
EP (8) | EP4182939A1 (en) |
JP (2) | JP2023534133A (en) |
CN (5) | CN116171478A (en) |
WO (8) | WO2022017891A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024107108A1 (en) * | 2022-11-14 | 2024-05-23 | National University Of Singapore | Computer implemented methods of generating dose recommendations |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180182475A1 (en) * | 2014-06-13 | 2018-06-28 | University Hospitals Cleveland Medical Center | Artificial-intelligence-based facilitation of healthcare delivery |
US20200176119A1 (en) * | 2018-11-30 | 2020-06-04 | Ariel Precision Medicine, Inc. | Methods and systems for severity calculator |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6349724B1 (en) * | 2000-07-05 | 2002-02-26 | Compumedics Sleep Pty. Ltd. | Dual-pressure blower for positive air pressure device |
US20050080348A1 (en) | 2003-09-18 | 2005-04-14 | Stahmann Jeffrey E. | Medical event logbook system and method |
US7591265B2 (en) * | 2003-09-18 | 2009-09-22 | Cardiac Pacemakers, Inc. | Coordinated use of respiratory and cardiac therapies for sleep disordered breathing |
US7680537B2 (en) | 2003-08-18 | 2010-03-16 | Cardiac Pacemakers, Inc. | Therapy triggered by prediction of disordered breathing |
EP1670547B1 (en) * | 2003-08-18 | 2008-11-12 | Cardiac Pacemakers, Inc. | Patient monitoring system |
US7468040B2 (en) * | 2003-09-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Methods and systems for implantably monitoring external breathing therapy |
SE0401208D0 (en) * | 2004-05-10 | 2004-05-10 | Breas Medical Ab | Multilevel fan |
EP2211687A4 (en) * | 2007-10-12 | 2013-08-21 | Patientslikeme Inc | Personalized management and monitoring of medical conditions |
US8775340B2 (en) * | 2008-12-19 | 2014-07-08 | The Board Of Trustees Of The University Of Illinois | Detection and prediction of physiological events in people with sleep disordered breathing using a LAMSTAR neural network |
CN102448368B (en) * | 2009-06-04 | 2015-05-27 | 皇家飞利浦电子股份有限公司 | Method and system for providing behavioural therapy for insomnia |
US8684006B2 (en) * | 2010-03-26 | 2014-04-01 | Advanced Brain Monitoring, Inc. | Systems and methods for optimizing oral appliance therapy for the treatment of sleep apnea |
WO2012071354A2 (en) * | 2010-11-23 | 2012-05-31 | Sanitas, Inc. | Disease management system using personalized education, patient support community and telemonitoring |
US20150282768A1 (en) * | 2012-09-29 | 2015-10-08 | Aliphcom | Physiological signal determination of bioimpedance signals |
US11712557B2 (en) * | 2013-05-30 | 2023-08-01 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
EP4133997A1 (en) * | 2013-07-08 | 2023-02-15 | ResMed Sensor Technologies Limited | A method carried out by a processor and system for sleep management |
NZ630770A (en) * | 2013-10-09 | 2016-03-31 | Resmed Sensor Technologies Ltd | Fatigue monitoring and management system |
US20190076031A1 (en) * | 2013-12-12 | 2019-03-14 | Alivecor, Inc. | Continuous monitoring of a user's health with a mobile device |
US9241079B1 (en) * | 2014-06-27 | 2016-01-19 | Sap Se | Mobile application usage monitor |
US10278638B2 (en) * | 2014-07-21 | 2019-05-07 | Withings | System and method to monitor and assist individual's sleep |
US20160106344A1 (en) * | 2014-10-14 | 2016-04-21 | Milad Nazari | Methods and systems for detecting movement disorder |
US9889271B2 (en) * | 2015-01-05 | 2018-02-13 | Inteliclinic Inc. | System, apparatus and method for treating sleep disorder symptoms |
AU2016205850B2 (en) | 2015-01-06 | 2018-10-04 | David Burton | Mobile wearable monitoring systems |
WO2016170005A1 (en) * | 2015-04-20 | 2016-10-27 | Resmed Sensor Technologies Limited | Detection and identification of a human from characteristic signals |
EP3302229A1 (en) * | 2015-05-29 | 2018-04-11 | Koninklijke Philips N.V. | System for increasing a patient's compliance with a therapy relating to an upper airway disorder |
US10582890B2 (en) * | 2015-08-28 | 2020-03-10 | Awarables Inc. | Visualizing, scoring, recording, and analyzing sleep data and hypnograms |
US10258272B2 (en) * | 2015-10-08 | 2019-04-16 | International Business Machines Corporation | Identifying stress levels associated with context switches |
CN117100245A (en) * | 2017-01-05 | 2023-11-24 | 诺克特丽克丝健康公司 | Restless leg syndrome or overactive nerve treatment |
US20190000349A1 (en) * | 2017-06-28 | 2019-01-03 | Incyphae Inc. | Diagnosis tailoring of health and disease |
US11363984B2 (en) * | 2017-09-12 | 2022-06-21 | Snooze, Inc. | Method and system for diagnosis and prediction of treatment effectiveness for sleep apnea |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
IL255255A0 (en) * | 2017-10-25 | 2017-12-31 | Optimata Ltd | System and method for prediction of medical treatment effect |
US20200268592A1 (en) * | 2017-10-26 | 2020-08-27 | Radial Medical, Inc. | Adaptive compression therapy systems and methods |
US11638795B2 (en) * | 2018-06-29 | 2023-05-02 | Koninklijke Philips N.V. | System and method for providing enhanced PAP metrics |
US11367519B1 (en) * | 2018-07-19 | 2022-06-21 | Great Lakes Neurotechnologies Inc. | Systems and methods for precision or personal pharmaceutical dosing |
WO2020047603A1 (en) | 2018-09-06 | 2020-03-12 | Monash University | Method of treating a sleep breathing disorder |
CL2019000057A1 (en) | 2019-01-08 | 2019-04-12 | Sleepmed Spa | Method and system for predicting risk index in conditions of chronic intermittent hypobaric hypoxia by recording physiological parameters and anthropometric variables in real time. |
CN114072827A (en) * | 2019-03-15 | 2022-02-18 | 3M创新有限公司 | Personalized medicine using causal models |
SG11202111929TA (en) * | 2019-05-02 | 2021-11-29 | Closed Loop Medicine Ltd | Methods and systems for providing personalised medicine to a patient |
US20210007659A1 (en) * | 2019-06-28 | 2021-01-14 | Teleplus Healthcare LLC | System and method for sleep disorders: screening, testing and management |
EP4003158A1 (en) * | 2019-07-25 | 2022-06-01 | Inspire Medical Systems, Inc. | Sleep detection for sleep disordered breathing (sdb) care |
US20220401689A1 (en) * | 2019-09-24 | 2022-12-22 | Delos Living Llc | Systems and methods for enhancing sleep patterns |
EP4038624A1 (en) * | 2019-09-30 | 2022-08-10 | ResMed Sensor Technologies Limited | Systems and methods for predicting adoption of a therapy |
CN114449944A (en) * | 2019-09-30 | 2022-05-06 | 豪夫迈·罗氏有限公司 | Disease state prediction |
US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
WO2021178353A1 (en) * | 2020-03-02 | 2021-09-10 | Sleep Number Corporation | Bed having user context sensing features |
CN113520340B (en) * | 2020-04-15 | 2022-11-08 | 华为技术有限公司 | Sleep report generation method, device, terminal and storage medium |
CN115836358A (en) * | 2020-04-30 | 2023-03-21 | 瑞思迈传感器技术有限公司 | System and method for facilitating sleep stages of a user |
-
2020
- 2020-11-30 US US17/106,827 patent/US11837106B2/en active Active
- 2020-12-23 US US17/132,503 patent/US20220020492A1/en active Pending
- 2020-12-23 US US17/132,424 patent/US20220020286A1/en active Pending
- 2020-12-30 US US17/138,272 patent/US20220016371A1/en active Pending
- 2020-12-30 US US17/138,242 patent/US20220016369A1/en active Pending
-
2021
- 2021-06-30 US US17/363,353 patent/US20220020468A1/en active Pending
- 2021-06-30 US US17/363,242 patent/US20220020463A1/en active Pending
- 2021-06-30 US US17/363,714 patent/US20220020461A1/en active Pending
- 2021-07-15 CN CN202180060534.1A patent/CN116171478A/en active Pending
- 2021-07-15 EP EP21751507.1A patent/EP4182939A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069677 patent/WO2022017891A1/en unknown
- 2021-07-15 EP EP21751506.3A patent/EP4182948A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069691 patent/WO2022017893A1/en unknown
- 2021-07-15 JP JP2022578701A patent/JP2023534133A/en active Pending
- 2021-07-16 EP EP21751771.3A patent/EP4182950A1/en active Pending
- 2021-07-16 WO PCT/EP2021/070052 patent/WO2022017991A1/en unknown
- 2021-07-16 EP EP21751773.9A patent/EP4182951A1/en active Pending
- 2021-07-16 JP JP2023503459A patent/JP2023537223A/en active Pending
- 2021-07-16 CN CN202180059498.7A patent/CN116210057A/en active Pending
- 2021-07-16 WO PCT/EP2021/070048 patent/WO2022017989A1/en unknown
- 2021-07-17 WO PCT/EP2021/070062 patent/WO2022017993A1/en unknown
- 2021-07-17 EP EP21751995.8A patent/EP4182953A1/en active Pending
- 2021-07-17 CN CN202180060076.1A patent/CN116171477A/en active Pending
- 2021-07-17 CN CN202180060209.5A patent/CN116134548A/en active Pending
- 2021-07-17 WO PCT/EP2021/070063 patent/WO2022017994A1/en unknown
- 2021-07-17 EP EP21751774.7A patent/EP4182952A1/en active Pending
- 2021-07-20 EP EP21754706.6A patent/EP4182938A1/en active Pending
- 2021-07-20 WO PCT/EP2021/070193 patent/WO2022018049A1/en unknown
- 2021-07-20 EP EP21754705.8A patent/EP4182954A1/en active Pending
- 2021-07-20 WO PCT/EP2021/070192 patent/WO2022018048A1/en unknown
- 2021-07-20 CN CN202180059048.8A patent/CN116134547A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180182475A1 (en) * | 2014-06-13 | 2018-06-28 | University Hospitals Cleveland Medical Center | Artificial-intelligence-based facilitation of healthcare delivery |
US20200176119A1 (en) * | 2018-11-30 | 2020-06-04 | Ariel Precision Medicine, Inc. | Methods and systems for severity calculator |
Also Published As
Publication number | Publication date |
---|---|
US20220020461A1 (en) | 2022-01-20 |
US20220020501A1 (en) | 2022-01-20 |
CN116134547A (en) | 2023-05-16 |
WO2022017994A1 (en) | 2022-01-27 |
WO2022017891A1 (en) | 2022-01-27 |
EP4182951A1 (en) | 2023-05-24 |
EP4182939A1 (en) | 2023-05-24 |
EP4182953A1 (en) | 2023-05-24 |
CN116171478A (en) | 2023-05-26 |
CN116210057A (en) | 2023-06-02 |
EP4182950A1 (en) | 2023-05-24 |
EP4182948A1 (en) | 2023-05-24 |
EP4182954A1 (en) | 2023-05-24 |
JP2023534133A (en) | 2023-08-08 |
WO2022018048A1 (en) | 2022-01-27 |
WO2022017991A1 (en) | 2022-01-27 |
US11837106B2 (en) | 2023-12-05 |
US20220020468A1 (en) | 2022-01-20 |
US20220016369A1 (en) | 2022-01-20 |
EP4182938A1 (en) | 2023-05-24 |
JP2023537223A (en) | 2023-08-31 |
WO2022018049A1 (en) | 2022-01-27 |
US20220020286A1 (en) | 2022-01-20 |
US20220020492A1 (en) | 2022-01-20 |
US20220016371A1 (en) | 2022-01-20 |
WO2022017989A1 (en) | 2022-01-27 |
CN116134548A (en) | 2023-05-16 |
CN116171477A (en) | 2023-05-26 |
EP4182952A1 (en) | 2023-05-24 |
WO2022017993A1 (en) | 2022-01-27 |
WO2022017893A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wass et al. | Individual differences in infant oculomotor behavior during the viewing of complex naturalistic scenes | |
Levy et al. | Safety behaviour enhances the acceptability of exposure | |
AU2015306075B2 (en) | A pain assessment method and system | |
Mohiyeddini et al. | Neuroticism and stress: The role of displacement behavior | |
Kai et al. | Effects of stretching on menopausal and depressive symptoms in middle-aged women: a randomized controlled trial | |
Hansson | Vestibular rehabilitation–For whom and how? A systematic review | |
Levit‐Binnun et al. | The relationship between sensory responsiveness profiles, attachment orientations, and anxiety symptoms | |
Talavera et al. | Subjective social status and rumination in relation to anxiety and depressive symptoms and psychopathology among economically disadvantaged Latinos in primary care. | |
Lafosse et al. | Contraversive pushing and inattention of the contralesional hemispace | |
US20220370757A1 (en) | Personalized sleep wellness score for treatment and/or evaluation of sleep conditions | |
Charbonneau et al. | Rhesus monkeys have an interoceptive sense of their beating hearts | |
Mathur et al. | Challenges of improving patient-centred care in Parkinson’s disease | |
Jeong et al. | Effects of saccular function on recovery of subjective dizziness after vestibular rehabilitation | |
van Deurs et al. | Sequential implementation of functional behavior assessment-informed treatment components for sleep disturbance in autism: A case study | |
US20220020463A1 (en) | Method and system to optimize pharmacotherapy | |
Nes et al. | Self‐regulatory fatigue: a missing link in understanding fibromyalgia and other chronic multisymptom illnesses | |
Rinaudo et al. | Comparison of incremental vestibulo-ocular reflex adaptation training versus x1 training in patients with chronic peripheral vestibular hypofunction: a two-year randomized controlled trial | |
Moreno-Gutierrez et al. | ATOPE+: an mHealth system to support personalized therapeutic exercise interventions in patients with cancer | |
van Dis et al. | Old fears die hard: Return of public speaking fear in a virtual reality procedure | |
Soriano et al. | Partner social constraints and early-stage breast cancer: Longitudinal associations with psychosexual adjustment. | |
Umeda et al. | Replication and extension of the link between the cardiovascular system and sensitivity to social pain in healthy adults | |
Saywell et al. | The role of the cerebellum in procedural learning—Are there implications for physiotherapists’ clinical practice? | |
Leung et al. | Real-time conscious postural control is not affected when balancing on compliant surface by young adults | |
Gutner et al. | The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals | |
EP4120898A1 (en) | Systems and methods involving sleep management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: KONINKLIJKE PHILIPS N.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, XIA;VON HOLLEN, DIRK ERNEST;GARSTECK, JAMES SCOTT;SIGNING DATES FROM 20220408 TO 20220420;REEL/FRAME:059658/0401 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |